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Introduction
More effective medical and surgical treatments for epilepsy have led to increasing interest in the condition and to a drive to improve the quality of services for people with epilepsy. We have sought to obtain a comprehensive and accurate profile of epilepsy in the community with the aim of contributing to the rational development of services. The data presented were drawn from a national sample of people with epilepsy and describe the demographic characteristics, severity and frequency of seizures, the utilization of anti-epileptic drugs (AEDs) and the impact of epilepsy on patients' lives. It was collected as part of a research enquiry into epilepsy services in the UK commissioned by CSAG (Clinical Standards Advisory Group). 1 The severity of epilepsy varies widely and any accurate assessment of the morbidity due to epilepsy must take this into account. Our first aim was, therefore, to determine the profile of disease severity in the general population by examining both seizure severity and frequency. In describing AED utilization, our main aim was to assess any changes in the patterns of utilization by comparison with previous studies. In particular, consensus treatment guidelines on polypharmacy and the choice of first line agents were previously found to have had limited impact. 2 We aimed to re-evaluate these aspects and examine the utilization of the ''new'' AEDs that have been licensed over the last decade. In addition to utilization, we sought to determine the severity of adverse effects of AEDs and their efficacy from the users' perspective, as these two factors have been found to be central determinants of the quality-of-life (QOL) in epilepsy. 3 The final aim of this study was to describe the impact of epilepsy on patients' lives from their own perspective and to test the hypothesis that the types of impact might significantly differ in different seizure severity groups and different age groups, as such differences are important for health care planning.
Method Case finding and recruitment
People with epilepsy were identified through 80 primary care practices, geographically distributed across the UK. All patients who were being prescribed AEDs for epilepsy (apart from febrile convulsions) were included and the sample, therefore, is representative of the overall population of patients with epilepsy in the country. The practices distributed 3455 questionnaires during May-October 1998. The method has been discussed in detail elsewhere. 4 The questionnaire and data analysis
The questionnaire asked about basic demographic details; the age of onset of epilepsy; severity of epilepsy; frequency of seizures; AEDs; and the impact of epilepsy on the patient's life. Seizure severity was assessed, in patients with one or more seizures within the last 12 months, using the National Hospital Seizure Severity Scale (NHS3), 5 with modifications in order to allow it to be self-completed. For children and patients with learning difficulties, the parents or carers were asked to help complete the form.
Subjects were asked how many drugs they were taking for epilepsy and asked to list them; they were asked how well they thought the drugs controlled their attacks and whether they experienced any side effects. For the latter two questions, four fixed responses were offered (for control: ''Very well''/''Fairly well''/''Not very well''/''Not at all well''; and for side effects: ''Severe''/''Moderate''/''Minor''/''None''). For quantitative analysis, the answers were scored from 0 to 3 in steps of one; a group score was obtained by calculating the mean score within the group. For ease of comprehension, this value was then scaled to a percentage. For example, all subjects responding ''None'' for the side effects question would result in a score of 0%; conversely, if all subjects responded ''Severe'', the score would be 100%. To assess impact on life, patients were asked to list (free-text) the major impacts of epilepsy on their life (up to three things).
For analysis of AED utilization, epilepsy severity, seizure severity and impact on life, the sample was divided into three age bands: less than 17 years, 17-65 years and over 65 years. The groups were compared using Chi-squared tests. In addition to age stratification, the impact on life data were analysed according to epilepsy severity based on the NHS3 which produces scores between 0 and 27. Patients with a NHS3 score above 15 were classified as having severe epilepsy and patients with a score of 15 or less were classified as having mild epilepsy, unless they had more than 10 seizures in the last 12 months, in which case they were classified as severe. We did not attempt to assess seizure severity in subjects who had no seizures within the preceding 12 months.
Comparison with previous studies
We compared the distribution of the age at first seizure with four epidemiological studies of epilepsy in the community. The age bands used to summarise the data in these studies differed in each paper and, therefore, to allow comparison to each, we calculated the age distribution in our sample using each of four age band groups used. and the mean duration of epilepsy was 19.7 years. One-thousand-and-sixty-two (64.3%) patients had epilepsy classified as mild and 537 (32.5%) severe; in the remaining 53 (3.2%), severity could not be determined due to deficiencies in questionnaire completion.
Ethical approval
In the analysis of 1064 cases from four epidemiological studies of epilepsy in the community in the USA, UK and Italy, there were 48% males and 52% females. Table 2 shows the distributions of age of first seizure in those studies in comparison with the present study using adjusted age bands.
Seizure severity and frequency
The details of seizure frequency and seizure severity are shown in Table 3 . There was a marked tendency for seizure frequency to decrease with increasing age which was significant comparing all age groups (χ 2 = 80.43, d.f. = 8, P < 0.0001). The mean NHS3 score in the three age bands differed significantly (Kruskal-Wallis χ 2 = 18.10, d.f. = 2, P < 0.0001).
The prevalence of severe epilepsy decreased with increasing age. The proportion of patients with severe epilepsy in the youngest group (51%) was significantly greater than that in the 17-65 years group (37%) (χ 2 = 65.7, d.f. = 1, P = 0.000), which was significantly greater than in the over 65 years group (17%) (χ 2 = 154.1, d.f. = 1, P = 0.000).
Anti-epileptic drug usage
Drug utilization and drug combinations Subjects were excluded if they did not list how many AEDs they were taking (1.9%) or they were not taking any AEDs (1.5%). In the latter case, AEDs had been discontinued in the interim between case identification and questionnaire completion. In all, 1499 were included (90.7% of the total sample). The mean number of AEDs being taken was 1.4 (range 1-7, median 1.0). The frequencies of use of each AED are shown in The details of the duration of epilepsy in groups of subjects on monotherapy taking different agents are shown in Table 4 . In this group, the mean duration of epilepsy in subjects taking phenobarbitone or primidone or phenytoin was 24.3 years (range 0-75), in comparison with 13.4 years (range 0-63) for carbamazepine or valproate, and 9.2 (0-36) years for lamotrigine or vigabatrin (Kruskal-Wallis over the three groups, P < 0.0001).
In the 366 subjects taking two AEDs, the most frequent combinations were phenytoin/phenobarbitone (17.8%), carbamazepine/valproate (16.1%), carbamazepine/phenytoin (8.5%), carbamazepine/ lamotrigne (7.7%), valproate/lamotrigine (7.1%), phenytoin/valproate (6%) and primidone/phenytoin (4.6%). These seven combinations accounted for 67.8% of the total number of combinations. In the group taking three AEDs, there were 56 different combinations which included 16 different drugs.
Seizure control and adverse effects of AEDs
Most subjects were satisfied with their seizure control (Table 5) When asked about the severity of adverse effects, 58.2% responded ''None'', 28.9% ''Minor'', 11.2% ''Moderate'' and 1.6% ''Severe''. The scores for adverse effects are shown in Table 5 .
For patients taking a single agent, the reported severity of adverse effects and duration of epilepsy, with stratification by the drug being taken are shown in Table 6 . The mean duration of epilepsy in patients on phenobarbitone was significantly higher than in the case of each of the other AEDs shown (Kruskal-Wallis over all five groups, P < 0.0001).
Impact on life
One-thousand-two-hundred-and-thirty-nine patients responded, listing between one and three impacts (median = 2, total 2576). These are 1499 1019 For the respondents on monotherapy, statistics on the duration of epilepsy are shown. As not all subjects responded to the question on the age at first seizure, the numbers shown are less than the total numbers on monotherapy. AEDs taken by less than 1% of subjects are not shown. summarized in Table 7 . The most notable difference between patients with mild and severe epilepsy was, in patients over 16 years old, the frequency of ''driving ban'' which was stated by 48% in the mild group in comparison with 28% in the severe group. The main impacts in adults of all ages were similar, with driving, work, psychological and social life being the commonest ones.
Discussion
This study was based on a large sample across the UK and patients with epilepsy regardless of aetiology, duration or age were included. Three factors, however, may have somewhat reduced the representativeness of the sample. Firstly, a proportion of the subjects will have been misdiagnosed as having epilepsy. In previous studies, estimates of the proportion of patients misdiagnosed have varied, but, as this was an observational study, were not in a position to confirm the diagnosis. 6 Secondly, case ascertainment was based upon AED prescription and therefore people with epilepsy who were not taking AEDs will have been missed but this proportion is likely to be small. 7 As the primary aim of this study was to obtain the users' perception of epilepsy services, we excluded patients who were not taking AEDs and, therefore, generally not accessing epilepsy services. Lastly, as expected from a postal questionnaire, the response rate was about 50%. Because of the requirement to maintain patient confidentiality, we were not able to obtain details of non-responders. However, the age and gender distribution and drug utilization in our sample conform to previous epidemiological studies of epilepsy, providing indirect evidence supporting the representative nature of our sample.
The severity of epilepsy in the community
Around half of the sample reported no seizures within the preceding twelve months. This is a Table 6 The severity of adverse medication effects reported by subjects on monotherapy.
AED
Adverse effect score (%) Duration of epilepsy (years) broadly similar proportion to that found in previous studies. 8 Although seizure severity was significantly lower in over 65 compared to younger adults, this difference was small and not of clear clinical significance. However, there was a marked tendency for seizure frequency to decrease with increasing age. It is impossible to determine, from a cross-sectional study, if this reflects the natural history of epilepsy or its different predominant aetiologies in different age groups. Probably both factors play a role. Whatever the reasons, this is obviously an important point when planning service provision, as patients in remission on treatment have quite different needs from those with ongoing epilepsy.
Anti-epileptic drug utilization
The pattern of utilization of AEDs for epilepsy in the community has received relatively little attention. Roberts et al.'s 9 analysis of AED utilization in the UK was based upon the overall prescription of AEDs in primary care, and would, therefore, have included prescriptions for conditions other than epilepsy, such as pain and psychiatric disorders, Social impacts include things such as fear of being alone, stress and acceptance of having epilepsy. ''None'' means that the respondent stated that they did not perceive any impacts on their life; it does not refer to non-responders.
which now a account for a significant proportion of prescriptions for all AEDs. Lambie et al., for example, found that 9.4% of prescriptions for AEDs were for conditions other than epilepsy. 10 In order to assess any changes in the utilization of AEDs for epilepsy, the most relevant study to compare the current one with is that of Hart and Shorvon's 2 which described AED utilization in 1051 patients with epilepsy, drawn from primary care in the UK in 1989. Sixty-five percent were on monotherapy, the most frequently used drugs being phenytoin (33%), carbamazepine (30%), valproate (25%) and phenobarbital (9%). In the present study, the proportion of patients on monotherapy was similar (69%) but there was considerable difference in the agents used. Valproate and carbamazepine were the most commonly used drugs (33 and 31%) in monotherapy and the use of phenytoin (24%) and phenobarbital (5%) appears to have fallen markedly. Hart and Shorvon's found that these four drugs accounted for 97% of those used in monotherapy whereas they accounted for 94% in our study, suggesting a modest impact of the ''new'' AEDs. Phenytoin and phenobarbital are not generally recommended as first line agents in epilepsy and fall in their use most likely reflects an increased awareness of this amongst doctors.
The duration of epilepsy in the subjects on monotherapy with phenobarbital, phenytoin or primidone, which are no longer recommended as first line treatment, was significantly greater (24.4 years) than that in subjects on monotherapy with carbamazepine or valproate (13.4 years). This also suggests that recent practice has changed in accordance with recommendations.
In common with other studies, we found a clear increase in the severity of adverse effects with increasing number of agents used. 11 This underlines the desirability of monotherapy, particularly as adverse effects are a major component in the diminishment of QOL in people with epilepsy. In particular, the combination of phenytoin and valproate should be avoided because of the danger of chronic phenytoin toxicity. 12 The data on the severity of adverse effects associated with individual agents should be interpreted with caution as the study was cross-sectional and the data cannot be taken as representative of the general adverse effect profiles of AEDs. Phenobarbital monotherapy was associated with a lower adverse effect score than was monotherapy with carbamazepine, valproate, phenytoin or lamotrigine but the mean duration of epilepsy in the subjects on phenobarbital monotherapy was significantly longer than for the other four AEDs. These subjects may well have been comprised largely of a self-selecting group of individuals tolerant to the agent. Conversely, the high level of adverse effects associated with lamotrigine may arise from a higher proportion of patients having been on it for a relatively short period, but many may subsequently discontinue the drug due to adverse effects.
The impact of epilepsy on patients' lives
The shift of emphasis in health service planning towards the users' perspective has driven the development of QOL measurement, particularly for chronic conditions. Several QOL measures have been developed specifically for epilepsy and have been applied to different patient groups, although mostly to patients with severe epilepsy. 13, 14 It has been found that QOL, particularly in psychological and psychosocial domains, is markedly diminished in patients with active epilepsy although it may be high in those with inactive epilepsy. 15 Seizure frequency and type and adverse effects of AEDs are important contributors to QOL impairment. 3 In the current study, we did not attempt to measure QOL as this was not feasible for a large cohort within the resources available. We asked patients to list, without prompts, the major impacts from their perspective. Whilst this is a simple approach, it has the advantages of being independent of the content validity of QOL measurements and, in previous studies, has been found to generate clearly defined areas of distress related to epilepsy. 16 In all age groups and severity groups, restriction of work/schooling were amongst the most frequently stated impacts. This is in accord with previous work which has shown that people with epilepsy suffer from excessive unemployment and limitation of choice and advancement in the workplace. In adults, driving was the second most prominent impact. It was, however, significantly less frequently listed by patients with severe epilepsy compared to those with mild epilepsy. The principal need to drive arises from the desire to achieve economic and social independence. It seems likely, that, in patients with severe epilepsy, these aspects may be so severely limited by other consequences of the condition that driving is less of a concern.
Epilepsy affects abut one in 150 people, of all ages and backgrounds. Our large population-based survey in the UK shows that almost half of all people currently on anti-epileptic drugs continue to have seizures, with continued impact of work, family and social life. Better medical care might improve the lives of people with epilepsy by achieving better seizure control through rational use of drugs and surgery.
